Acrivon Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Acrivon Therapeutics, Inc. (ACRV) reported Debt Securities, Available-for-sale, Unrealized Loss of $133.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-12-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-12-15
- 2022-09-30: Debt Securities, Available-for-sale, Unrealized Loss 9 month $133.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 9 month |
|---|---|
| 2022-09-30 | $133.00K 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |